EBIO - Eleven Biotherapeutics, Inc.

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE10 months ago

    Biotech Company, ENDV Should Be On Everyone's Watchlist

    HENDERSON, NV / ACCESSWIRE / June 19, 2018 / ENDV officially announced the enrollment of their first patient in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company's senior secured Series C Preferred Stock financing. With the recent advancement of companies who specialize in brain injuries and trauma advancing at a tremendous rate there is plenty of reason for optimism.

  • ACCESSWIRE11 months ago

    Blog Exposure - ADMA Biologics Received US Patent for Treating Respiratory Infections

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMA as the Company's latest news hit the wire. On May 16, 2018, the New Jersey-based biopharmaceutical Company announced that the United States Patent and Trademark Office has issued to ADMA US Patent No. 9,969,793 covering methods of treating respiratory infections. Active-Investors.com is currently working on the research report for Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), which also belongs to the Healthcare sector as the Company ADMA Biologics.

  • ACCESSWIRE11 months ago

    Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.

  • Business Wire11 months ago

    Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio

    Eleven Biotherapeutics, Inc. (EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that the company is changing its name to Sesen Bio, Inc. Sesen Bio will trade under the new Nasdaq ticker symbol “SESN,” effective on May 17, 2018. The new website for Sesen Bio is www.sesenbio.com. Additionally, the company announced the appointments of Hagop Youssoufian, M.Sc., M.D. as senior medical advisor and Madhu Anant M.Sc., Ph.D., RAC as vice president of regulatory affairs.

  • Business Wire11 months ago

    Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates

    Eleven Biotherapeutics, Inc. , a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today reported pipeline updates and operating results for the quarter ended March 31, 2018.

  • Implied Volatility Surging for Eleven Biotherapeutics (EBIO) Stock Options
    Zackslast year

    Implied Volatility Surging for Eleven Biotherapeutics (EBIO) Stock Options

    Investors in Eleven Biotherapeutics (EBIO) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRElast year

    Today’s Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / There was no catalyst or news to send shares of both Midatech and Eleven Biotherapeutics higher on Wednesday. Midatech Pharma Plc shares closed up 10.56% yesterday with more gains seen in after-hours trading as well. There was no significant news from the specialty pharmaceutical company to explain the move up.

  • ACCESSWIRElast year

    Today's Research Reports on Trending Tickers: Eleven Biotherapeutics and CVS Health

    NEW YORK, NY / ACCESSWIRE / April 23, 2018 / U.S. markets dropped Friday as positive corporate earnings were offset by losses from the technology and consumer staples sectors. The yield on the 10-year ...

  • Who Are The Largest Shareholders In Eleven Biotherapeutics Inc (NASDAQ:EBIO)?
    Simply Wall St.last year

    Who Are The Largest Shareholders In Eleven Biotherapeutics Inc (NASDAQ:EBIO)?

    In this article, I’m going to take a look at Eleven Biotherapeutics Inc’s (NASDAQ:EBIO) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher
    Zackslast year

    Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher

    Shares of Eleven Biotherapeutics (EBIO) rose nearly 9% yesterday.

  • ACCESSWIRElast year

    With FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like Move

    Newly public NeuroOne (NMTC) could be one of these movers in 2018 as they plan to file their first FDA medical device submission in the upcoming months. This technology addresses a large market opportunity and could support multiples of upside.